Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024

Core Insights - Kyverna Therapeutics has reported positive clinical data for KYV-101, a treatment for severe lupus nephritis, showing sustained efficacy and durability at over six months follow-up [1][3] - The treatment demonstrated robust safety and tolerability, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed [1] - KYV-101 appears to reset the immune system, stabilize estimated glomerular filtration rate (eGFR), and preserve kidney function while reducing the need for immunosuppressants [3] Clinical Data Presentation - Updated clinical data will be presented at a symposium titled "KYV-101 Anti-CD19 CAR T-Cell Therapy: The Future of Autoimmune Disease Treatment" on November 18, 2024 [2] - The presentation will include data from ongoing Phase 1/2 studies and named patient treatments, highlighting the outcomes of six patients treated with the target dose of 1×10^8 CD19 CAR T cells [1][2] Patient Impact - Lupus nephritis poses a significant burden, with up to 30% of patients facing end-stage renal disease requiring dialysis or kidney transplants [3][6] - Current treatments often fail to provide adequate efficacy and expose patients to harmful long-term effects of corticosteroids and immunosuppressants [6] Next-Generation Approaches - Kyverna will also present data on Ingenui-T, a preclinical 3-day manufacturing process using autologous whole blood, aimed at improving patient experience and reducing costs [4] - Collaborative research on the molecular mechanisms of immune reset through deep B-cell depletion will be shared, conducted with Verily Life Sciences and the University of Erlangen [5] Company Overview - Kyverna Therapeutics is focused on developing cell therapies for autoimmune diseases, with KYV-101 being evaluated in multiple clinical trials for various conditions, including lupus nephritis [8] - The company aims to provide innovative treatment options that are well-suited for B cell-driven autoimmune diseases [8]